Breaking News

Caris Life Sciences and Hummingbird Bioscience Enter Strategic Collaboration

Will advance clinical development of Hummingbird Bioscience's anti-HER3 therapy, HMBD-001.

Author Image

By: Charlie Sternberg

Associate Editor

Caris Life Sciences, a molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, have entered a strategic collaboration to advance clinical development of Hummingbird Bioscience’s anti-HER3 therapy, HMBD-001.   Hummingbird Bioscience, a clinical-stage biotech...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters